Repositioning Candidate Details

Candidate ID: R0634
Source ID: DB04873
Source Type: investigational
Compound Type: small molecule
Compound Name: Piboserod
Synonyms: Piboserod
Molecular Formula: C22H31N3O2
SMILES: CCCCN1CCC(CNC(=O)C2=C3OCCCN3C3=CC=CC=C23)CC1
Structure:
DrugBank Description: Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.
CAS Number: 152811-62-6
Molecular Weight: 369.5004
DrugBank Indication: For the treatment of atrial fibrillation and irritable bowel syndrome (IBS).
DrugBank Pharmacology: GlaxoSmithKline was investigating piboserod, a 5HT4 antagonist, for the treatment of atrial fibrillation. Phase II trials were ongoing in March 2004, but by December of that year, development had been discontinued. Piboserod had previously being investigated for the treatment of irritable bowel syndrome (IBS), but development for this indication was terminated in 1999.
DrugBank MoA: Piboserod appears to act as a specific antagonist of one of the receptors for 5-hydroxytryptamine, the 5-HT4 receptor. The 5-HT4 receptor antagonists are thought to antagonize both the ability of serotonin to sensitize the peristaltic reflex and 5-HT-induced defecation, at least in animal studies. As 5-HT4 receptors are present in human atrial cells and when stimulated may cause atrial arrhythmias, piboserod was under investigation in clinical trials for atrial fibrillation.
Targets: 5-hydroxytryptamine receptor 4
Inclusion Criteria: Indication associated